48 results on '"Yu, H.A."'
Search Results
2. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
3. COVID-19 in patients with lung cancer
4. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
5. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
6. POSing the question: MARIPOSA-2, do the ends justify the means?
7. P2.09-14 Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations
8. P2.10-06 Brain Metastases in Patients with Fusion-Positive Lung Cancers
9. The stability of TNT, RDX and PETN in simulated post-explosion soils: Implications of sample preparation for analysis
10. Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers
11. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
12. 329P ORCHARD: Osimertinib + necitumumab in patients (pts) with advanced NSCLC whose disease progressed on first-line (1L) osimertinib
13. 1195TiP HERTHENA-Lung02: A randomized phase III study of patritumab deruxtecan vs platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC after progression with a third-generation EGFR TKI
14. 1190TiP Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
15. EP16.03-030 AKT Inhibition as a Therapeutic Strategy to Constrain Histological Transdifferentiation in EGFR-mutant Lung Adenocarcinoma.
16. 1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
17. EP.12A.03 Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
18. 1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab
19. 13P Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
20. POSing the question: MARIPOSA-2, do the ends justify the means?
21. 1MO Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation
22. 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
23. 1800O Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation
24. OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
25. 1319MO Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01
26. P01.04 Dynamics of Molecular Markers in EGFR-Mutated NSCLC Patients Treated with Patritumab Deruxtecan (HER3-DXd; U3-1402)
27. 169P Phase I dose escalation trial combining olaparib and thoracic radiation therapy in extensive-stage small cell lung cancer
28. LBA62 Efficacy and safety of patritumab deruxtecan (U3-1402), a novel HER3 directed antibody drug conjugate, in patients (pts) with EGFR-mutated (EGFRm) NSCLC
29. 1345P Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
30. Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
31. Fundamental studies of the adhesion of explosives to textile and non-textile surfaces
32. 1506TiP - Phase I study of the AXL inhibitor DS-1205c in combination with osimertinib in subjects with metastatic or unresectable EGFR-mutant NSCLC
33. Risk of Brain Metastasis in EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Prophylactic Cranial Irradiation?
34. 10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer
35. Pattern of Failure in Metastatic EGFR-Mutant NSCLC Treated With Erlotinib: A Role for Upfront Radiation Therapy?
36. EGFR Exon 20 Alterations in Lung Adenocarcinomas and Their Impact on Overall Survival and Response to EGFR TKI
37. A Phase Ib Dose-Escalation Study of the Hsp90 Inhibitor Snx-5422 and Erlotinib in Patients with Egfr-Mutant Lung Cancer and Acquired Resistance to Egfr Tyrosine Kinase Inhibitors
38. Post-dural puncture headache after spinal anesthesia and perioperative blood pressure
39. 1288P - A Phase Ib Dose-Escalation Study of the Hsp90 Inhibitor Snx-5422 and Erlotinib in Patients with Egfr-Mutant Lung Cancer and Acquired Resistance to Egfr Tyrosine Kinase Inhibitors
40. C2 DOMAIN OF CYTOSOLIC PHOSPHOLIPASE A2, NMR, MINIMIZED AVERAGE STRUCTURE
41. HUMAN INTERLEUKIN-6, NMR, MINIMIZED AVERAGE STRUCTURE
42. HUMAN INTERLEUKIN-6, NMR, 32 STRUCTURES
43. A carbonaceous thin film made by CVD and its application for a carbon/n-type silicon (C/n-Si) photovoltaic cell
44. The carbonaceous film made by chemical vapor deposition of 2,5-dimethyl-p-benzoquinone (2) — electronic properties
45. Carbonaceous Thin Films Made by Chemical Vapor Deposition of 2, 5-Dimethyl-p-benzoquinone (1)
46. Carbonaceous thin films made by chemical vapor deposition of 2,5-dimethyl-p-benzoquinone (1).- Preparation and structure
47. A turbostratic carbon with high specific surface area from 1,4-benzenedimethanol
48. Photovoltaic cell of carbonaceous film/n-type silicon.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.